Overview

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Amgen
Onyx Pharmaceuticals